About this trial
This research study is looking at tumor tissue samples from patients who have undergone surgery for advanced stage III or stage IV ovarian epithelial cancer. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn how tumor infiltrating T cells can predict how patients will respond to treatment.
Eligibility criteria
Qualifiers
Diagnosis of stage III or IV ovarian epithelial cancer and enrolled on Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial (GOG-0114, GOG-132, GOG-0158, or GOG-0162)
Patients enrolled on GOG-0136 and a GOG front-line platinum/taxol chemotherapy trial(GOG-0114, GOG-0132, GOG-0158, and GOG-0162)
Patients who have had either optimal or suboptimal cytoreductive surgery
Patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected
Disqualifiers
None
Trial design
Treatments tested in this trial
- Laboratory Biomarker Analysis
Treatment groups
Sponsors and collaborators
Gynecologic Oncology Group
Lead sponsor
National Cancer Institute (NCI)
Collaborator